Study details
Enrolling now
Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia
Massachusetts General Hospital
NCT IDNCT07238400ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
90
Study length
about 3.3 years
Ages
18–55
Sex
Female only
Locations
2 sites in MA
What this study is about
Researchers are testing whether eplerenone, a medication, improves coronary microvascular function better than chlorthalidone in women who had preeclampsia. The trial will last 1215 days and involve taking either eplerenone + potassium or chlorthalidone + potassium daily for 48 weeks.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Chlorthalidone 25 mg daily
- 2.Take Eplerenone 100 mg daily
- 3.Take Potassium Chloride
- +1 more
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
OralOral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
chlortalidone, eplerenone, potassium chloride
Drug routes
oral (Oral Tablet)
Body systems
Cardiology / Heart